Drug Profile
Alicapistat - AbbVie
Alternative Names: ABT-957Latest Information Update: 30 Jan 2018
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Amides; Pyrrolidines; Small molecules
- Mechanism of Action Calpain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 30 Jan 2018 Chemical structure information added
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In adults) in USA
- 30 Jun 2016 Abbvie terminates a phase I trial for Alzheimer's disease (In adults, In elderly) in USA (NCT02573740) due to insufficient target engagement of ABT 957 as per preclinical data